Article

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer

2022-04-14

Abstract excerpt

<h4>ABSTRACT</h4> Prostate cancer (PCa) harboring BRCA1/2 mutations is often exquisitely sensitive to PARP inhibition. However, genomic alterations in other DNA damage response genes have not been consistently predictive of clinical response to PARP inhibitors (PARPis). Here, we perform genome-wide CRISPR-Cas9 knockout screens in BRCA1/2-proficient PCa cell lines and identify novel genes whose loss has a profound...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 668cb314-7704-5c36-80ca-a4bdee349b8e
DOI: 10.1101/2022.04.13.488115

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancerDOI 10.1101/2022.04.13.488115Read

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancerSemantic proximity Read

Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibitionSemantic proximity Read

Drug–gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP InhibitionSemantic proximity Read

A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivitiesSemantic proximity Read

Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer.Semantic proximity Read

CRISPR screens guide the way for PARP and ATR inhibitor biomarker discoverySemantic proximity Read

RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancerSemantic proximity Read

RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancerSemantic proximity Read

CRISPR Screen Contributes to Novel Target Discovery in Prostate CancerSemantic proximity Read

A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 InhibitorSemantic proximity Read

BRCA2 reversion mutation-independent resistance to PARP inhibition in prostate cancer through loss of function perturbations in the DNA pre-replication complexSemantic proximity Read

CRISPR screening identifies novel PARP inhibitor classification based on distinct base excision repair pathway dependenciesSemantic proximity Read